Atopic Dermatitis - Drug Pipeline Landscape, 2022

Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.

Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an immune system response that causes the inflamed skin and other symptoms.

Atopic dermatitis (eczema) symptoms include dry, cr*cked skin, itchiness, rash, bumps, on brown or black skin, oozing and crusting, thickened skin, darkening of the skin around the eyes, raw, sensitive skin from scratching.

Read more about Atopic Dermatitis - Drug Pipeline here: https://www.globalinsightservices.com/reports/atopic-dermatitis-drug-pipeline-landscape-2022/

Healthcare provider will diagnose eczema examining the skin. However, the following tests may be performed for confirmation, an allergy skin test, blood tests and a skin biopsy to distinguish one type of dermatitis from another.

Treatment of atopic dermatitis starts with moisturizing and self-care habits. These are sometimes combined with other treatments like medications and therapies. Medications including products applied to the skin, anti-infective drugs and anti-inflammatories. Therapies like wet dressings, light therapy and counselling may also help based on the severity.

There are many clinical trials ongoing in atopic dermatitis drug development. Some of the most promising trials are studying new treatments for atopic dermatitis, such as biologic drugs. Biologic drugs are made from living cells and are designed to target specific parts of the immune system. They have the potential to be more effective and have fewer side effects than traditional drugs. Other clinical trials are studying new ways to deliver existing treatments, such as through patches or creams.

To remain 'ahead' of your competitors, request for a sample: https://www.globalinsightservices.com/request-sample/GIS31002/

Methodology:

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope:

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Get a Customized Scope to Match Your Need Ask an Expert: https://www.globalinsightservices.com/request-customization/GIS31002/

Key Players:

• 3SBio Inc
• AbbVie
• Aclaris Therapeutics, Inc.
• Akaal Pharma Pty Ltd
• Akesobio Australia Pty Ltd
• Allakos, Inc.
• Amgen

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.